Gilead Sciences Reports Improving Revenue in the 2nd Quarter
You might say the first quarter of 2019 was a turning point for Gilead Sciences (NASDAQ: GILD). For the first time in quite a while, the big biotech reported revenue and earnings growth. It was also the first quarter with Gilead's new CEO, Daniel O'Day, at the helm.
Investors found out if Gilead could keep its momentum going when the company announced its second-quarter results after the market closed on Tuesday. Here are the highlights from Gilead's quarterly update.
Image source: Getty Images.
Quelle Fool.com
